FcRn inhibitors for myasthenia gravis
Cochrane Database of Systematic Reviews · 2025
DOI: 10.1002/14651858.cd016097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cochrane Database of Systematic Reviews, 2025. Verfasst von Laura M White und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lancaster Medical School, Lancaster University, Lancaster, UK. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Fc, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of FcRn inhibitors for the maintenance treatment of myasthenia gravis in adult participants compared with control treatment (placebo, standard-of-care therapy, an alternative FcRn inhibitor, or an alternative immunomodulatory therapy). We will evaluate the efficacy of the treatment by the effect on disease severity and functional impairment, as assessed using a measurement tool validated for use in myasthenia gravis. Where possible, we will assess whether the effects of FcRn inhibitors differ according to different participant subgroups or different treatment regimens, or both. These data will be used to inform policymakers on the participant subgroups most likely to benefit from treatment and the most efficacious treatment regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lancaster Medical School, Lancaster University, Lancaster, UK.
- Department of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
- Department of Forensic Medicine, Monash University, Southbank, Australia.
- University of Tasmania, Hobart, Australia.
- Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK.
- The University of Manchester, Manchester, UK.
ORCID-Profile: Katherine C Dodd
Zitieren
APA
White, L. M., Clay, F. J., Forbes, A. M., Keh, R. Y. S., Lilleker, J. B., Spillane, J., Storms, K., Dodd, K. C., & Sussman, J. (2025). FcRn inhibitors for myasthenia gravis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd016097
Vancouver
White LM, Clay FJ, Forbes AM, Keh RYS, Lilleker JB, Spillane J, et al. FcRn inhibitors for myasthenia gravis. Cochrane Database of Systematic Reviews. 2025. doi:10.1002/14651858.cd016097
BibTeX
@article{White2025,
author = {White, Laura M and Clay, Fiona J and Forbes, Anne-Marie and Keh, Ryan Yann Shern and Lilleker, James B and Spillane, Jennifer and Storms, Karen and Dodd, Katherine C and Sussman, Jon},
title = {FcRn inhibitors for myasthenia gravis},
journal = {Cochrane Database of Systematic Reviews},
year = {2025},
doi = {10.1002/14651858.cd016097}
}
EUVIMED